CARLSBAD, Calif. (AP) _ GenMark Diagnostics Inc. (GNMK) on Tuesday reported a loss of $12.1 million in its first quarter.
The Carlsbad, California-based company said it had a loss of 21 cents per share.
The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for a loss of 21 cents per share.
The molecular diagnostics company posted revenue of $21.5 million in the period, which topped Street forecasts. Three analysts surveyed by Zacks expected $21.1 million.
GenMark Diagnostics expects full-year revenue in the range of $85 million to $90 million.
GenMark Diagnostics shares have risen 49% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $7.22, a climb of 15% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on GNMK at https://www.zacks.com/ap/GNMK